Prediction of Key Candidate Genes for Platinum Resistance in Ovarian Cancer
Kaidi Guo,Li Li
DOI: https://doi.org/10.2147/IJGM.S338044
IF: 2.145
2021-11-16
International Journal of General Medicine
Abstract:Kaidi Guo, 1, 2, &ast Li Li 1, 2, &ast 1 Department of Gynecology and Oncology, Guangxi Medical University Cancer Hospital, Nanning, Guangxi, People's Republic of China; 2 Key Laboratory of Early Prevention and Treatment for Regional High Frequency Tumor, Ministry of Education, Nanning, Guangxi, People's Republic of China &astThese authors contributed equally to this work Correspondence: Li Li Department of Gynecology and Oncology, Guangxi Medical University Cancer Hospital, Nanning, Guangxi, 530021, People's Republic of China Tel +86 138 7811 3406 Email Purpose: Ovarian cancer is one of the common malignant tumors of female reproductive organs, which seriously threatens the life and health of women. Resistance to chemotherapeutic drugs for ovarian cancer is the root cause of recurrence in most patients. The purpose of this study is to determine the differentially expressed genes of platinum resistance in ovarian cancer, and to screen out molecular targets and diagnostic markers that could be used to treat ovarian cancer platinum resistance. Methods: We downloaded 5 gene microarray datasets GSE58470, GSE45553, GSE41499, GSE33482, and GSE15372 from the Gene Expression Omnibus database, all of which are associated with ovarian cancer platinum resistance. Subsequently, the intersection of the statistically significant differentially expressed genes in 5 gene chips was taken, and relevant bioinformatics and clinical parameters were performed on the screened differential genes. qRT-PCR was utilized to examine the mRNA expression levels in ovarian cancer sensitive and cisplatin-resistant cells. Results: Three differential genes, IFI27, JAG1, DNM3 , may be closely related to platinum resistance of ovarian cancer, were screened by microarray datasets. According to the combined verification of bioinformatics, clinical case analyses and experiments, it was inferred that the increased expression of DNM3 was beneficial to patients with platinum resistance, but the high expression of IFI27 and JAG1 may lead to the risk of platinum resistance. Conclusion: IFI27, JAG1 and DNM3 screened by relevant gene chips may serve as new biomarkers of platinum resistance in ovarian cancer. Keywords: ovarian cancer, platinum resistance, bioinformatical analysis, differentially expressed genes Ovarian cancer is one of the common malignancies of female reproductive organs, which seriously threatens the life and health of women. Because the ovaries are deep in the pelvic cavity, small in size, lack of typical symptoms, and effective screening methods, it is difficult to detect early. About 75% of patients with ovarian cancer have been diagnosed as advanced stage, with peritoneal spread or distant metastasis. 1,2 Tumor cytoreductive surgery combined with postoperative adjuvant chemotherapy is a common clinical treatment for patients with advanced ovarian cancer. Chemotherapy drugs for ovarian cancer mainly include periodic non-specific platinum and cycle-specific paclitaxel. Platinum hinders DNA synthesis and mitosis in cancer cells by cross-linking with DNA, while paclitaxel can strengthen tubulin polymerization and inhibit tubulin depolymerization. 3 However, even if the initial chemotherapy treatment effect is good, most patients are prone to multidrug resistance, that is, as long as the resistance to one of the chemotherapeutic drugs, they will be resistant to other chemotherapy drugs with different structures and mechanisms. As the most commonly used chemotherapeutic drug in clinical practice, platinum is quite frequently resistant in the treatment of ovarian cancer. At present, the widely used detection indicators for ovarian cancer lack specificity and sensitivity. Therefore, it is urgent to discover the marker genes related to platinum resistance in ovarian cancer. Keywords: "ovarian carcinoma" OR "ovarian cancer" OR "chemotherapy resistance" OR "platinum resistance"; restricted species was "Homo sapiens", to search for gene expression profiles related to platinum resistance in ovarian cancer that had been publicly reported in the GEO before 2021. Finally, 21 datasets were retrieved. (1) The dataset must be a comparative study on platinum-sensitivity and resistance of ovarian cancer; (2) The downloaded data is the original dataset or standardized processing; (3) Each group of control (sensitive) and case (resistant) in the dataset must include or exceed 3 samples; (4) Clear information on the sensitivity and resistance of each sample to platinum must be given. Datasets that meet the above criteria will be included in this study. In the end, there are 5 datasets t -Abstract Truncated-
medicine, general & internal